BioSpace News Archive

Elevar Therapeutics, Inc. today announced it will hold a formal presentation on Sept. 28 at the Cantor Fitzgerald Global Healthcare Conference in New York.

Krystal Biotech, Inc. announced today that the U.S. Food and Drug Administration (FDA) cleared the Investigational New Drug Application (IND) for KB408 for the treatment of alpha-1 antitrypsin deficiency (AATD).

Transcend Therapeutics, a biotechnology company developing rapid-acting treatments for neuropsychiatric diseases, announced receipt of a collaborative grant award with Yale University to support first-of-its-kind preclinical research on methylone – Transcend’s lead compound for the treatment of post-traumatic stress disorder (PTSD).

Altasciences is pleased to have been chosen by Virpax Pharmaceuticals, Inc. (NASDAQ:VRPX) (“Virpax”), a company specializing in developing non-addictive products for pain management, PTSD, central nervous system (CNS) disorders, and viral barrier indications, to conduct preclinical studies in support of their development of quaternary ammonium palmitoyl glycol chitosan (GCPQ, under the trade name of AnQlar™).

In a study published online in CELL , scientists at UCSF QBI, University College London and the Icahn School of Medicine at Mount Sinai reported breakthrough findings on convergent evolutionary mechanisms shared by COVID-19 variants, allowing them to overcome both adaptive and innate immune system barriers.

South Rampart Pharma, Inc. announced that it has been awarded The Commercialization Readiness Pilot Program grant by the NIH, NINDS for its application entitled ‘Novel non-narcotic analgesic for acute and chronic pain.’

There might be a lack of General Internal Medicine physicians by the year 2032, which could cause implications for health care and delivery across the United States.

Breakthrough Properties, a premier global life sciences real estate developer, announced that it has reached an agreement with Neogene Therapeutics to develop its new European headquarters within the campus of the Amsterdam University Medical Center (Amsterdam UMC), one of Europe’s leading medical institutions.

NKGen Biotech, Inc. (“NKGen” or the “Company”), a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous, allogeneic, and CAR-NK natural killer (“NK”) cell therapies, today announced that its Executive Leadership will present at the Cantor Fitzgerald 2023 Global Healthcare Conference on Wednesday, September 27, 2023, in New York City.

Stryker, one of the world’s leading medical technology companies, continues its year of milestones celebration with the 10th anniversary of the Triathlon Tritanium baseplate.